Prostatic hyperplasia
Conditions
Interventions
control group:Tamsulosin Hydrochloride Sustained Release Capsule
treatment group:Qianlong Shutong Formula+Tamsulosin Hydrochloride Sustained Release Capsule
Sponsors
Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine
Eligibility
Sex/Gender
Male
Age
50 Years to 75 Years
Inclusion criteria
Inclusion criteria: ? Meet the diagnostic criteria of traditional Chinese medicine or western medicine; ? Patients aged 50-75 years; ? International Prostate Symptom Score (IPSS) for mild patients (IPSS<7) and moderate patients (7 = IPSS = 20); ? Number of nocturnal urination = 3 times; ? The symptoms of benign prostatic hyperplasia appear for more than three months, and the residual urine volume measured is greater than 50ml; ? Patients who have good compliance, can adhere to medication, and receive regular follow-up visits; ? Those who have signed an informed consent form and voluntarily joined the study;
Exclusion criteria
Exclusion criteria: ? Those who do not meet the inclusion criteria; ? There are also other urogenital diseases, such as prostatitis, neurogenic bladder, urethral stricture, etc.; ? Having undergone prostate surgery or other special treatment; ? Patients with various chronic diseases, psychiatric patients, and liver and kidney dysfunction; ? Allergic to observation drug; ? Those who are allergic to this drug or do not use it according to regulations, unable to judge the efficacy or incomplete information, which may affect the efficacy or safety judgment; ? Persons who have not participated in other clinical trials
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| International Prostate Symptom Score;TCM syndrome score;Determination of residual urine volume in the bladder;Quality of life index score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Liver and renal function; | — |
Countries
china
Contacts
Public Contactze-chao ZHANG
Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine
Outcome results
None listed